Childhood cutaneous hemangiomas

Cutis

Volumn 72, Issue 3, 2003, Pages 201-205

  Altman, Rachel S ^a   Schwartz, Robert A ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; CORTICOSTEROID; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; CRYOSURGERY; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG EFFICACY; FEVER; HISTOPATHOLOGY; HUMAN; LASER SURGERY; NEUTROPENIA; SKIN HEMANGIOMA; SKIN NECROSIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR DIAGNOSIS;

CHILD; CHILD, PRESCHOOL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HEMANGIOMA; HUMANS; INFANT; INFANT, NEWBORN; SOFT TISSUE NEOPLASMS; VASCULAR NEOPLASMS;

EID: 0141889979     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ezekowitz AB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life threatening hemangiomas of infancy. N Engl J Med. 1992;329:1456-1463.
2. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412-422.
3. Frieden IJ, Garzon M, Enjolras R. Vascular tumors and vascular malformations: does overlap occur? In: Program and abstracts of the 12th International Workshop on Vascular Anomalies; June 27-28, 1998; Berlin, Germany. Abstract.
4. Holmdahl K. Cutaneous hemangiomas in premature and mature infants. Acta Paediatr. 1955;44:370.
5. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999;341:173-181.
6. Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg. 1983;18:894-900.
7. Chang J, Most D, Bresnick S, et al. Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg. 1999;103:1-9.
8. Cheung DS. Hemangioma in twins. Ann Plast Surg. 1997;38:269-274.
9. Siegel AM, Andermann E, Badhwar A, et al. Anticipation in familial cavernous angioma: a study of 52 families from International Familial Cavernous Angioma Study. IFCAS Group. Lancet. 1998;352:1676-1677.
10. Rigamonti D, Hadley MN, Drayer BP, et al. Cerebral cavernous malformations, incidence and familial occurrence. N Engl J Med. 1988;319:343-347.
11. Zabramski JM, Wascher TM, Spetzler RE et al. The natural history of familial cavernous malformations: results of an ongoing study. J Neurosurg. 1994;80:422-432.
12. Burton BK, Schultz CJ, Angle B, et al. An increased incidence of haemangiomas in infants born following chorionic villus sampling (CVS). Prenat Diagn. 1995;15:209-214.
13. Quintero RA, Romero R, Mahoney MJ, et al. Embryonic demonstration of hemorrhagic lesions on the human embryo after placental trauma. Am J Obstet Gynecol. 1993;168:756-759.
14. Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol. 1997;37:631-637.
15. Payne MM, Moyer F, Marcks KM, et al. The precursor to the hemangioma. Plast Reconstr Surg. 1996;38:64-67.
16. Hidano A, Nakajima S. Earliest features of the strawberry mark in the newborn. Br J Dermatol. 1972;87:138-144.
17. Boon LM, Enjolras O, Mulliken JB. Congenital hemangioma: evidence of accelerated involution. J Pediatr. 1996;128:329-335.
18. Esterly NB. Kasabach-Merritt syndrome in infants. J Am Acad Dermatol. 1983;8:504-513.
19. Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr. 1997;130:631-640.
20. MacArthur CJ, Senders CW, Katz J. The use of interferon alfa-2a for life threatening hemangiomas. Arch Otolaryngol Head Neck Surg. 1995;121:690-693.
21. Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg. 1997;100:1377-1386.
22. Kunkeler A, Uitdehaag B, Stoof TJ. Familial cavernous hemangiomas. Br J Dermatol. 1998;139:166-167.
23. Frieden IJ, Resse V, Cohen D. PHACE syndrome: the association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996;132:307-311.
24. Burns J, Kaplan LC, Mulliken JB. Is there an association between hemangioma and syndromes with dysmorphic features? Pediatrics. 1991;88:1257-1267.
25. Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatr Dermatol. 1997;14:173-179.
26. Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a "beard" distribution. J Pediatr. 1997;131:643-646.
27. Schoen FJ, Cotran RS. Blood vessels. In: Cotran RS, Kumar V, Collins T, eds. Pathologic Basis of Disease. 6th ed. Philadelphia, Pa: WB Saunders Co; 1999:493-541.
28. Mooney MA, Janniger CK. Pyogenic granuloma. Cutis. 1995;55:133-136.
29. Schwartz RA, Dabski C, Dabska M. The Dabska tumor: a thirty-year retrospect. Dermatology. 2000;201:1-5.
30. Frieden IJ. Which hemangiomas to treat - and how? Arch Dermatol. 1997;133:1593-1595.
31. Munn SE, Jackson JE, Russell JR. Tufted haemangioma responding to high dose systemic steroids: a case report and review of the literature. Clin Exp Dermatol. 1994;19:511-514.
32. Enjolras O, Riche MC, Merland JJ, et al. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics. 1990;85:491-498.
33. Barlow C, Priebe CJ, Mulliken JB, et al. Neurotoxicity in the treatment of hemangiomas with interferon alpha 2a. In: Proceedings of the 11th International Workshop on Vascular Anomalies; June 24, 1996; Rome, Italy. Abstract.
34. Illum N, Karlsmark T, Svejgaard E, et al. Ulcerated haemangioma successfully treated with interferon alpha-2b and topical granulocyte-macrophage colony-stimulating factor. Dermatology. 1995;191:315-317.
35. Barlow CF, Priebe C, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132:527-530.
36. Greinwald JH Jr, Burke DK, Bonthius DJ, et al. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg. 1999;125:21-27.
37. Tamayo L, Ortiz DM, Orozco-Covarrubias L, et al. Therapeutic efficacy of interferon alfa-2b in infants with life threatening giant hemangiomas. Arch Dermatol. 1997;133:1567-1571.
38. Reischle S, Schuller-Petrovic S. Treatment of capillary hemangiomas of early childhood with a new method of cryosurgery. J Am Acad Dermatol. 2000;42:809-813.
39. Spicer MS, Goldberg DJ. Lasers in dermatology. J Am Acad Dermatol. 1996;34:1-25.
40. Goldman MP, Fitzpatrick RE. Treatment of cutaneous vascular lesions. In: Goldman MP, Fitzpatrick RE, eds. Cutaneous Laser Surgery: The Art and Science of Selective Photothermolysis. St Louis, Mo: Mosby; 1994:92-104.
41. Werner JA, Lippert BM, Godbersen GS, et al. Treatment of hemangioma with the neodymium:yttrium-aluminum-garnet laser (Nd:YAG laser). Laryngorhinootologie. 1992;71:388-395.
42. Burstein FD, Simms C, Cohen SR, et al. Intralesional laser therapy of extensive hemangiomas in 100 consecutive pediatric patients. Ann Plast Surg. 2000;44:188-194.
43. Mulliken JB. Management of hemangiomas [abstract]. Pediatr Dermatol. 1997;14:60.